Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.

Thrombolysis with tissue-type plasminogen activator (t-PA) is the only treatment approved for acute ischemic stroke. Although t-PA is an efficient clot lysis enzyme, it also causes damage to the neurovascular unit, including hemorrhagic transformations and neurotoxicity.